J Vial, P Huchedé, S Fagault, F Basset, M Rossi, J Geoffray, H Soldati, J Bisaccia, M H Elsensohn, M Creveaux, D Neves, J Y Blay, F Fauvelle, F Bouquet, N Streichenberger, N Corradini, C Bergeron, D Maucort-Boulch, P Castets, M Carré, K Weber, M Castets
Rhabdomyosarcoma (RMS) is the most frequent form of pediatric soft-tissue sarcoma. It is divided into two main subtypes: ERMS (embryonal) and ARMS (alveolar). Current treatments are based on chemotherapy, surgery, and radiotherapy. The 5-year survival rate has plateaued at 70% since 2000, despite several clinical trials. RMS cells are thought to derive from the muscle lineage. During development, myogenesis includes the expansion of muscle precursors, the elimination of those in excess by cell death and the differentiation of the remaining ones into myofibers...
July 24, 2020: Cell Death Discovery